AstraZeneca's ZS-9 Timeline Hit By FDA Complete Response Letter

A manufacturing issue at a plant in Texas has resulted in a complete response letter from the FDA, dashing AstraZeneca's hopes that its potential best-in-class treatment for hyperkalemia, ZS-9, would be approved in this year's first half – but the good news is that no new clinical data is required on the drug.

The regulatory timeline for AstraZeneca PLC's promising potassium-binding compound ZS-9 has been derailed for the time being by a complete response letter from the FDA due to manufacturing deficiencies found by investigators during a pre-approval inspection at a plant making the medicine in Coppell, Texas.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America